Virtual Investor is a leading platform providing investors with direct access to innovative companies, management teams and thought leaders.
Covered Companies
Covered Companies
Series
What This Means
July 22, 2026
Abizer Gaslightwala, Director, President and Chief Executive Officer of Akari Therapeutics discusses the significance of the Whitehawk collaboration and how it represents an important opportunity to evaluate Akari’s proprietary PH1 spliceosome modulating payload technology in combination with Whitehawk’s topoisomerase I inhibitor (TOP1i) ADC platform.
What This Means
July 15, 2026
Rob Berman, CEO discusses the Company’s recent news announcing the issuance of the first U.S. Patent covering the company’s enVVe® system, further expanding its intellectual property portfolio and laying the groundwork to dominate the large and untapped replacement venous valve market.
What This Means
Moleculin
July 06, 2026
Walter Klemp, Chairman and Chief Executive Officer of Moleculin discusses the positive preliminary unblinded efficacy results from the first 45 patients enrolled in Part A of the pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in relapsed or refractory acute myeloid leukemia (R/R AML).
What This Means
June 25, 2026
Sabrina Martucci Johnson, President and CEO of Daré Bioscience, discusses tthe upcoming launch of Flora Sync LF5™ and its significance as the company’s first consumer health product and opportunity to generate direct product revenue.
KOL Connect
Ernexa Therapeutics Pharma
June 09, 2026
Ira S. Winer, MD, PhD, FACOG, Scientific Advisory Board Member at Ernexa Therapeutics, Professor in the Division of Gynecologic Oncology at Wayne State University School of Medicine and gynecologic oncologist at the Barbara Ann Karmanos Cancer Institute, provides perspective on the significant unmet need that continues to exist in ovarian cancer, limitations associated with current treatment approaches and the growing focus on overcoming immunologically “cold” tumors that remain resistant to many immune-based therapies.
What This Means
CNS Pharma
June 08, 2026
Steve O’Loughlin, Chief Financial Officer of CNS Pharmaceuticals, discusses the Company’s recently completed oversubscribed $22.5 million financing, addressing the factors that enabled the successful capital raise following its strategic reset and acquisition-focused transformation.
What This Means
Featuring Autonomix
June 04, 2026
Dr. Toufic Kachaamy, Key Opinion Leader and Chief of Medicine at City of Hope in Phoenix, AZ, discusses the clinical significance of data presented by Autonomix Medical at the Society of Surgical Oncology Annual Meeting (SSO), highlighting the importance of the work being selected for a podium presentation and its relevance to the surgical oncology community.
What This Means
Featuring AIM ImmunoTech
June 04, 2026
AIM Chief Executive Officer Thomas Equels, Consulting Medical Officer Charles Lapp, MD, and Consulting Science Officer Christopher Nicodemus, MD, examine current Ebola outbreak concerns, unmet need surrounding the Bundibugyo strain and Ampligen’s previously published antiviral research.
What This Means
Featuring Moleculin
June 04, 2026
Walter Klemp, Chairman and Chief Executive Offier of Moleculin, discusses the Company’s recent news announcing that the 45th subject has been enrolled in its pivotal Phase 2B/3 MIRACLE trial evaluating Annamycin in combination with cytarabine (AnnAraC) for the treatment of adult subjects with relapsed or refractory acute myeloid leukemia (R/R AML).
What This Means
May 28, 2026
Abizer Gaslightwala, President and CEO of Akari Therapeutics highlights the significance of Akari’s first ASCO abstract acceptance and discussed newly presented preclinical data demonstrating combination synergy between Akari’s differentiated spliceosome-modulating ADC platform and a KRAS inhibitor in KRAS-mutated pancreatic cancer models.
CEO Connect
Featuring CNS Pharmaceuticals
May 20, 2026
Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals, highlighted the Company’s recent $22.5 million financing, including its strategic pivot, progress made to date and how the capital positions CNS to identify and advance new assets aimed at driving long-term shareholder value.
KOL Connect
Featuring Ernexa Therapeutics
May 20, 2026
Dr. Elena Ratner, Professor in the Department of Obstetrics, Gynecology and Reproductive Sciences at Yale University School of Medicine and a member of Ernexa’s Board of Directors, discusses the evolving ovarian cancer treatment landscape and shares her perspective on Ernexa’s differentiated biological approach to addressing immunologically “cold” tumors.
KOL Connect
Featuring AIM Immuno
May 14, 2026
Professor Doctor Casper H.J. van Eijck, MD, PhD, Professor and Pancreato-biliary Surgeon at Erasmus Medical Center (“Erasmus MC”) and a consultant for AIM, and AIM Chief Executive Officer Thomas K. Equels, MS, JD, participate in a Virtual Investor KOL Connect segment.
Prof. Dr. van Eijck, a globally recognized pancreatic cancer clinical expert and the foremost expert in the use of Ampligen in pancreatic cancer, examines Ampligen’s mechanism of action, its potential to provide a positive immunotherapeutic approach, existing clinical data, development strategy, and anticipated regulatory milestones, supporting AIM’s focused commitment to advancing a potential new treatment option for patients with late-stage pancreatic cancer.
What This Means
Featuring enVVeno Medical
May 12, 2026
Robert Berman, Chief Executive Officer of enVVeno Medical, discusses the Company’s recent news announcing the U.S. Food and Drug Administration’s (FDA) first-ever IDE approval awarded to enVVeno to proceed with a U.S. pivotal study of a non-surgical replacement venous valve.
Past Events
CEO Connect
Closing Bell
Closing Bell Series
Closing Bell
